Total Payments
$52,042
2024 Payments
$39,081
Companies
50
Transactions
241
Medicare Patients
2,580
Medicare Billing
$1.3M
Payment Breakdown by Category
Other$38,514 (74.0%)
Travel$7,663 (14.7%)
Food & Beverage$5,865 (11.3%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $38,514 | 13 | 74.0% |
| Travel and Lodging | $7,663 | 18 | 14.7% |
| Food and Beverage | $5,865 | 210 | 11.3% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $47,393 | 52 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $452.71 | 20 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $341.25 | 9 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $296.97 | 14 | $0 (2024) |
| Janssen Biotech, Inc. | $278.72 | 11 | $0 (2024) |
| Myriad Genetic Laboratories, Inc. | $244.37 | 4 | $0 (2024) |
| PFIZER INC. | $240.10 | 11 | $0 (2024) |
| Genentech USA, Inc. | $226.33 | 10 | $0 (2024) |
| Daiichi Sankyo Inc. | $166.07 | 6 | $0 (2024) |
| Bayer Healthcare Pharmaceuticals Inc. | $139.84 | 6 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $39,081 | 129 | Merck Sharp & Dohme LLC ($36,920) |
| 2023 | $12,185 | 85 | Merck Sharp & Dohme LLC ($10,449) |
| 2022 | $776.07 | 27 | E.R. Squibb & Sons, L.L.C. ($245.87) |
All Payment Transactions
241 individual payment records from CMS Open Payments — Page 2 of 10
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/06/2024 | Novartis Pharmaceuticals Corporation | Fabhalta (Drug) | Food and Beverage | In-kind items and services | $33.17 | General |
| Category: Immunology | ||||||
| 11/01/2024 | Janssen Biotech, Inc. | DARZALEX (Biological), TALVEY, TECVAYLI | Food and Beverage | In-kind items and services | $38.07 | General |
| Category: Oncology | ||||||
| 10/31/2024 | PFIZER INC. | ELREXFIO (Drug), ADCETRIS | Food and Beverage | In-kind items and services | $22.66 | General |
| Category: ONCOLOGY | ||||||
| 10/29/2024 | Janssen Biotech, Inc. | TECVAYLI (Biological), TALVEY, DARZALEX | Food and Beverage | In-kind items and services | $24.05 | General |
| Category: Oncology | ||||||
| 10/28/2024 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Food and Beverage | In-kind items and services | $21.97 | General |
| Category: Oncology | ||||||
| 10/24/2024 | Mirati Therapeutics, Inc. | KRAZATI (Drug) | Food and Beverage | Cash or cash equivalent | $18.39 | General |
| Category: Oncology | ||||||
| 09/25/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $34.47 | General |
| 09/16/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $17.33 | General |
| Category: ONCOLOGY | ||||||
| 09/12/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $29.56 | General |
| Category: ONCOLOGY | ||||||
| 09/08/2024 | SOBI, INC | DOPTELET (Drug) | Food and Beverage | In-kind items and services | $18.82 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 09/06/2024 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $20.96 | General |
| Category: Hematology | ||||||
| 09/05/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $14.37 | General |
| 09/04/2024 | Rigel Pharmaceuticals, Inc. | Rezlidhia (Drug), Tavalisse | Food and Beverage | Cash or cash equivalent | $22.41 | General |
| Category: Acute Myeloid Leukemia | ||||||
| 08/26/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $28.35 | General |
| Category: ONCOLOGY | ||||||
| 08/23/2024 | Alnylam Pharmaceuticals Inc. | GIVLAARI (Drug) | Food and Beverage | In-kind items and services | $16.33 | General |
| Category: Genetic Disease | ||||||
| 08/21/2024 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | In-kind items and services | $26.42 | General |
| Category: Oncology | ||||||
| 08/20/2024 | Janssen Biotech, Inc. | ERLEADA (Drug), AKEEGA | Food and Beverage | In-kind items and services | $28.50 | General |
| Category: Oncology | ||||||
| 08/19/2024 | Genentech USA, Inc. | Phesgo (Biological) | Food and Beverage | In-kind items and services | $20.80 | General |
| Category: BioOncology | ||||||
| 08/15/2024 | Azurity Pharmaceuticals, Inc. | VIVIMUSTA (Drug) | Food and Beverage | In-kind items and services | $19.23 | General |
| Category: ONCOLOGY | ||||||
| 08/14/2024 | Bayer Healthcare Pharmaceuticals Inc. | Nubeqa (Drug), Xofigo | Food and Beverage | In-kind items and services | $25.08 | General |
| Category: Oncology | ||||||
| 08/13/2024 | ABBVIE INC. | IMBRUVICA (Drug) | Food and Beverage | In-kind items and services | $29.23 | General |
| Category: ONCOLOGY | ||||||
| 08/12/2024 | AstraZeneca Pharmaceuticals LP | ENHERTU (Biological) | Food and Beverage | In-kind items and services | $27.73 | General |
| Category: Oncology | ||||||
| 08/07/2024 | Kite Pharma, Inc. | Yescarta (Drug) | Food and Beverage | In-kind items and services | $24.22 | General |
| Category: CELLT | ||||||
| 08/06/2024 | Immunocore Limited | KIMMTRAK (Drug) | Food and Beverage | In-kind items and services | $22.30 | General |
| Category: Oncology | ||||||
| 08/02/2024 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Food and Beverage | In-kind items and services | $20.86 | General |
| Category: ONCOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 39 | 2,023 | 79,654 | $4.8M | $1.3M |
| 2022 | 22 | 557 | 3,245 | $289,134 | $74,588 |
Total Patients
2,580
Total Services
82,899
Medicare Billing
$1.3M
Procedure Codes
61
All Medicare Procedures & Services
61 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J9271 | Injection, pembrolizumab, 1 mg | Office | 2023 | 16 | 6,800 | $856,800 | $293,110 | 34.2% |
| J9299 | Injection, nivolumab, 1 mg | Office | 2023 | 12 | 11,900 | $844,900 | $283,384 | 33.5% |
| J9144 | Injection, daratumumab, 10 mg and hyaluronidase-fihj | Office | 2023 | 13 | 6,300 | $858,780 | $239,700 | 27.9% |
| J1437 | Injection, ferric derisomaltose, 10 mg | Office | 2023 | 53 | 6,100 | $453,100 | $102,825 | 22.7% |
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 21 | 4,500 | $229,500 | $84,181 | 36.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 239 | 654 | $188,636 | $68,393 | 36.3% |
| J0881 | Injection, darbepoetin alfa, 1 microgram (non-esrd use) | Office | 2023 | 46 | 23,600 | $495,600 | $55,449 | 11.2% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 96 | 270 | $185,220 | $30,226 | 16.3% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 127 | 127 | $49,033 | $16,348 | 33.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 136 | 158 | $31,995 | $11,826 | 37.0% |
| 96401 | Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 22 | 172 | $35,260 | $10,387 | 29.5% |
| J0185 | Injection, aprepitant, 1 mg | Office | 2023 | 24 | 7,020 | $63,180 | $9,632 | 15.2% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 43 | 43 | $21,681 | $7,153 | 33.0% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 223 | 822 | $28,770 | $6,249 | 21.7% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 92 | 120 | $36,480 | $6,247 | 17.1% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2023 | 38 | 103 | $34,402 | $5,699 | 16.6% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2023 | 67 | 221 | $33,592 | $5,432 | 16.2% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 28 | 34 | $13,592 | $5,095 | 37.5% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 63 | 276 | $28,980 | $3,626 | 12.5% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 136 | 333 | $6,327 | $2,797 | 44.2% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 93 | 228 | $21,204 | $2,689 | 12.7% |
| 96415 | Administration of chemotherapy into vein, each additional hour | Office | 2023 | 19 | 106 | $16,536 | $2,550 | 15.4% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 21 | 21 | $6,237 | $2,053 | 32.9% |
| 96360 | Infusion into a vein for hydration, 31-60 minutes | Office | 2023 | 20 | 39 | $9,711 | $1,083 | 11.2% |
| 99497 | Advance care planning, first 30 minutes | Office | 2023 | 14 | 14 | $2,646 | $963.76 | 36.4% |
About Najeff Waseem
Najeff Waseem is a Medical Oncology healthcare provider based in Baltimore, Maryland. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/14/2016. The National Provider Identifier (NPI) number assigned to this provider is 1598119711.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Najeff Waseem has received a total of $52,042 in payments from pharmaceutical and medical device companies, with $39,081 received in 2024. These payments were reported across 241 transactions from 50 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($38,514).
As a Medicare-enrolled provider, Waseem has provided services to 2,580 Medicare beneficiaries, totaling 82,899 services with total Medicare billing of $1.3M. Data is available for 2 years (2022–2023), covering 61 distinct procedure/service records.
Ad
Practice Information
- Specialty Medical Oncology
- Location Baltimore, MD
- Active Since 04/14/2016
- Last Updated 09/16/2021
- Taxonomy Code 207RX0202X
- Entity Type Individual
- NPI Number 1598119711
Products in Payments
- KEYTRUDA (Biological) $42,948
- WELIREG (Drug) $2,275
- OPDIVO (Biological) $276.84
- PRECISETUMOR (Device) $219.68
- LIBTAYO (Biological) $117.34
- VERZENIO (Drug) $115.05
- Enhertu (Drug) $113.77
- CABOMETYX (Drug) $112.46
- ICLUSIG (Drug) $106.72
- ERLEADA (Drug) $100.75
- IBRANCE (Drug) $94.60
- FOTIVDA (Drug) $91.03
- KISQALI (Drug) $88.80
- IMFINZI (Biological) $86.81
- PLUVICTO (Drug) $84.82
- Nubeqa (Drug) $82.93
- KRAZATI (Drug) $81.31
- VENCLEXTA (Drug) $77.85
- SCEMBLIX (Drug) $77.75
- Columvi (Biological) $72.17
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Medical Oncology Doctors in Baltimore
Mario Eisenberger, M.d, M.D
Medical Oncology — Payments: $2.9M
Medical Oncology $2.9M
Dr. Tanguy Seiwert, M.d, M.D
Medical Oncology — Payments: $622,422
Medical Oncology $622,422
Carole Miller, Md, MD
Medical Oncology — Payments: $587,841
Medical Oncology $587,841
Bruce Smith, M.d, M.D
Medical Oncology — Payments: $406,689
Medical Oncology $406,689
Carol Huff, M.d, M.D
Medical Oncology — Payments: $384,580
Medical Oncology $384,580
Leisha Emens
Medical Oncology — Payments: $252,501
Medical Oncology $252,501